ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last661 to 680 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Nonfatal Stroke83 of 6,767

83 of 6,756

-0.0 points

-0.4 to 0.4

13,523NCT02185417

Diuretic Comparison Project

Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Hospitalization for Heart Failure232 of 6,767

242 of 6,756

-0.2 points

-0.8 to 0.5

13,523NCT02185417

Diuretic Comparison Project

Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Unstable Angina Leading to Urgent Coronary Revascularization13 of 6,767

20 of 6,756

-0.1 points

-0.3 to 0.1

13,523NCT02185417

Diuretic Comparison Project

Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Deceased and Not Related to Cancer354 of 6,767

359 of 6,756

-0.1 points

-0.8 to 0.7

13,523NCT02185417

Diuretic Comparison Project

Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Nonfatal Myocardial Infarction140 of 6,767

142 of 6,756

-0.0 points

-0.5 to 0.5

13,523NCT02185417

Diuretic Comparison Project

Hydrochlorothiazide vs Chlorthalidone: deaths from any cause448 of 6,767

446 of 6,756

0.0 points

-0.8 to 0.9

13,523NCT02185417

Diuretic Comparison Project

Hydrochlorothiazide vs Chlorthalidone: serious adverse events1,977 of 6,767

1,990 of 6,756

-0.2 points

-1.8 to 1.3

13,523NCT02185417

Diuretic Comparison Project

Prasugrel vs Clopidogrel: serious adverse events1,731 of 6,741

1,675 of 6,716

0.7 points

-0.7 to 2.2

13,457NCT00097591

A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

TICAGRELOR vs CLOPIDOGREL: Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization569 of 6,732

668 of 6,676

-1.6 points

-2.5 to -0.6

13,408NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

With Dyslipidaemia vs Without Dyslipidaemia: Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Dyslipidaemia)99 of 5,308

109 of 8,035

0.5 points

0.1 to 1.0

13,343NCT01252563

Amlodipine 10mg Drug Use Investigation

With Complication(s) vs Without Complication(s): Number of Participants With Treatment-Related Adverse Events: With/Without Complication(s)170 of 9,177

38 of 4,166

0.9 points

0.5 to 1.3

13,343NCT01252563

Amlodipine 10mg Drug Use Investigation

With ARB vs Without ARB: Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (ARB)118 of 6,641

90 of 6,702

0.4 points

0.0 to 0.9

13,343NCT01252563

Amlodipine 10mg Drug Use Investigation

Male vs Female: Number of Participants With Treatment-Related Adverse Events: Male vs. Female87 of 7,504

121 of 5,839

-0.9 points

-1.4 to -0.5

13,343NCT01252563

Amlodipine 10mg Drug Use Investigation

With Angina Pectoris vs Without Angina Pectoris: Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Angina Pectoris)21 of 872

187 of 12,471

0.9 points

0.0 to 2.2

13,343NCT01252563

Amlodipine 10mg Drug Use Investigation

With Antihypertensive vs Without Antihypertensive: Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (Antihypertensive)136 of 7,834

72 of 5,509

0.4 points

0.0 to 0.8

13,343NCT01252563

Amlodipine 10mg Drug Use Investigation

Part B (Blinded): mRNA-1273 at Month 6 vs Part B (Blinded): mRNA-1273.222 at Month 6: Part B: Number of Participants With Serious Adverse Events (SAEs)212 of 11,243

45 of 2,012

-0.4 points

-1.1 to 0.3

13,255NCT05168813

Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

Part B (Blinded): mRNA-1273 at Month 6 vs Part B (Blinded): mRNA-1273.222 at Month 6: Part B: Number of Participants With Adverse Events of Special Interest (AESIs)111 of 11,243

27 of 2,012

-0.4 points

-1.0 to 0.1

13,255NCT05168813

Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Composite of Stroke/MI/Death442 of 6,589

497 of 6,610

-0.8 points

-1.7 to 0.1

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Ischaemic Stroke385 of 6,589

441 of 6,610

-0.8 points

-1.7 to -0.0

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With CV Death41 of 6,589

35 of 6,610

0.1 points

-0.2 to 0.4

13,199NCT01994720

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=34

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02185417-61970e8e",
        "title": "Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Nonfatal Stroke",
        "summary": "83 of 6767 against 83 of 6756; risk difference -0.0 points, 95% interval -0.4 to 0.4; NCT02185417, Diuretic Comparison Project",
        "record": "/library/comparisons/NCT02185417-61970e8e",
        "nct_id": "NCT02185417",
        "kind": "outcome",
        "participants": 13523,
        "risk_difference": {
          "value": -0.000019970317065638732,
          "lower": -0.0037723881504740323,
          "upper": 0.003731200726633902
        },
        "group_1": "83 of 6,767",
        "group_2": "83 of 6,756",
        "difference": "-0.0 points",
        "interval": "-0.4 to 0.4",
        "trial_title": "Diuretic Comparison Project"
      },
      {
        "id": "NCT02185417-acddd0d7",
        "title": "Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Hospitalization for Heart Failure",
        "summary": "232 of 6767 against 242 of 6756; risk difference -0.2 points, 95% interval -0.8 to 0.5; NCT02185417, Diuretic Comparison Project",
        "record": "/library/comparisons/NCT02185417-acddd0d7",
        "nct_id": "NCT02185417",
        "kind": "outcome",
        "participants": 13523,
        "risk_difference": {
          "value": -0.0015359864238591106,
          "lower": -0.007759840347928783,
          "upper": 0.004680352091816752
        },
        "group_1": "232 of 6,767",
        "group_2": "242 of 6,756",
        "difference": "-0.2 points",
        "interval": "-0.8 to 0.5",
        "trial_title": "Diuretic Comparison Project"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=35",
  "request_id": "MeQvXP8-u-4vWEBv"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?